Company: MDCXW
Filing Date: 2025-12-08
Form Type: 8-K
Source: 0001062993-25-017219
Chunk: 3

Company: Medicus Pharma Ltd.
Filing Date: 2025-12-08
Form: 8-K
Item: Item 7.01
Chunk 3
---
Item 7.01 Regulation FD Disclosure.

A press release announcing entry into the Agreement, described in Item 1.02 herein, is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

  Exhibit      Description                                                                   
      No.                                                                                    
 ─────────────────────────────────────────────────────────────────────────────────────────────
      4.1      Form of Series C Warrant                                                      
      4.2      Form of Series D Warrant                                                      
     10.1      Form of Warrant Inducement Agreement                                          
     99.1      Press Release, dated December 5, 2025                                         
    104.1      Cover Page Interactive Data File (embedded within the inline XBRL document).  

Forward-Looking Statements

Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the closing of the Company's issuance of the New Warrants and the timing thereof, any sales by the investor of Common Shares underlying the Existing Warrants or the New Warrants, the timing and effectiveness of the Registration Statement, whether the Shareholder Approval will be obtained, if required and any future sales of Common Shares under the SEPA to Yorkville. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "could," "designed," "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target", "potential" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to